These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 23140144)

  • 1. Targeted drug delivery for cancer therapy: the other side of antibodies.
    Firer MA; Gellerman G
    J Hematol Oncol; 2012 Nov; 5():70. PubMed ID: 23140144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies.
    Amani N; Dorkoosh FA; Mobedi H
    Curr Drug Deliv; 2020; 17(1):23-51. PubMed ID: 31755387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-targeted drugs and drug resistance--challenges and solutions.
    Shefet-Carasso L; Benhar I
    Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multivalent protein-drug conjugates - An emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells.
    Porębska N; Ciura K; Chorążewska A; Zakrzewska M; Otlewski J; Opaliński Ł
    Biotechnol Adv; 2023 Oct; 67():108213. PubMed ID: 37453463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Drug Conjugates: A Review on the Epitome of Targeted Anti- Cancer Therapy.
    Hasan M; Alam S; Poddar SK
    Curr Clin Pharmacol; 2018; 13(4):236-251. PubMed ID: 30073930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
    Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
    J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current methods for the synthesis of homogeneous antibody-drug conjugates.
    Sochaj AM; Świderska KW; Otlewski J
    Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide-drug conjugates: A new paradigm for targeted cancer therapy.
    Wang M; Liu J; Xia M; Yin L; Zhang L; Liu X; Cheng Y
    Eur J Med Chem; 2024 Feb; 265():116119. PubMed ID: 38194773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads.
    Aguiar S; Dias J; Manuel AM; Russo R; Gois PMP; da Silva FA; Goncalves J
    Adv Protein Chem Struct Biol; 2018; 112():143-182. PubMed ID: 29680236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent antibody drug conjugates for cancer therapy.
    Senter PD
    Curr Opin Chem Biol; 2009 Jun; 13(3):235-44. PubMed ID: 19414278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers.
    Peng H
    Antib Ther; 2021 Oct; 4(4):222-227. PubMed ID: 34805745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxime-Linked Peptide-Daunomycin Conjugates as Good Tools for Selection of Suitable Homing Devices in Targeted Tumor Therapy: An Overview.
    Mező G; Gomena J; Ranđelović I; Dókus EL; Kiss K; Pethő L; Schuster S; Vári B; Vári-Mező D; Lajkó E; Polgár L; Kőhidai L; Tóvári J; Szabó I
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Learn from antibody-drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy.
    Wu M; Huang W; Yang N; Liu Y
    Exp Hematol Oncol; 2022 Nov; 11(1):93. PubMed ID: 36348391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy.
    Lindberg J; Nilvebrant J; Nygren PÅ; Lehmann F
    Molecules; 2021 Oct; 26(19):. PubMed ID: 34641586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
    Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
    Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-drug conjugates as targeted cancer therapeutics.
    Sun Y; Yu F; Sun BW
    Yao Xue Xue Bao; 2009 Sep; 44(9):943-52. PubMed ID: 20055167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery.
    Richards DA
    Drug Discov Today Technol; 2018 Dec; 30():35-46. PubMed ID: 30553519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Organic Synthesis in the Emergence and Development of Antibody-Drug Conjugates as Targeted Cancer Therapies.
    Nicolaou KC; Rigol S
    Angew Chem Int Ed Engl; 2019 Aug; 58(33):11206-11241. PubMed ID: 31012193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.